109 related articles for article (PubMed ID: 38875109)
1. Mathematical modelling, selection, and hierarchical inference to determine the minimal dose in IFNα therapy against Myeloproliferative Neoplasms.
Hermange G; Vainchenker W; Plo I; Cournède PH
Math Med Biol; 2024 Jun; ():. PubMed ID: 38875109
[TBL] [Abstract][Full Text] [Related]
2. Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms.
Hermange G; Cournède PH; Plo I
J Pharmacol Exp Ther; 2023 Oct; 387(1):31-43. PubMed ID: 37391225
[TBL] [Abstract][Full Text] [Related]
3. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
Mosca M; Hermange G; Tisserand A; Noble R; Marzac C; Marty C; Le Sueur C; Campario H; Vertenoeil G; El-Khoury M; Catelain C; Rameau P; Gella C; Lenglet J; Casadevall N; Favier R; Solary E; Cassinat B; Kiladjian JJ; Constantinescu SN; Pasquier F; Hochberg ME; Raslova H; Villeval JL; Girodon F; Vainchenker W; Cournède PH; Plo I
Blood; 2021 Dec; 138(22):2231-2243. PubMed ID: 34407546
[TBL] [Abstract][Full Text] [Related]
4. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
[TBL] [Abstract][Full Text] [Related]
5. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
King KY; Matatall KA; Shen CC; Goodell MA; Swierczek SI; Prchal JT
Exp Hematol; 2015 Oct; 43(10):912-918.e2. PubMed ID: 26072330
[TBL] [Abstract][Full Text] [Related]
6. The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms.
Yoon SY; Won JH
Blood Res; 2021 Apr; 56(S1):S44-S50. PubMed ID: 33935035
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
8. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.
Boklund TI; Snyder J; Gudmand-Hoeyer J; Larsen MK; Knudsen TA; Eickhardt-Dalbøge CS; Skov V; Kjær L; Hasselbalch HC; Andersen M; Ottesen JT; Stiehl T
Front Immunol; 2024; 15():1384509. PubMed ID: 38846951
[TBL] [Abstract][Full Text] [Related]
9. Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells.
Saleiro D; Kosciuczuk EM; Fischietti M; Perez RE; Yang GS; Eckerdt F; Beauchamp EM; Hou Y; Wang Q; Weinberg RS; Fish EN; Yue F; Hoffman R; Platanias LC
Cancer Res Commun; 2023 May; 3(5):943-951. PubMed ID: 37377894
[TBL] [Abstract][Full Text] [Related]
10. The possible role of mutated endothelial cells in myeloproliferative neoplasms.
Farina M; Russo D; Hoffman R
Haematologica; 2021 Nov; 106(11):2813-2823. PubMed ID: 34320782
[TBL] [Abstract][Full Text] [Related]
11. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
Lu M; Xia L; Li Y; Wang X; Hoffman R
Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
[TBL] [Abstract][Full Text] [Related]
12. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
Morishita S
Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
[TBL] [Abstract][Full Text] [Related]
13. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.
Knudsen TA; Skov V; Stevenson K; Werner L; Duke W; Laurore C; Gibson CJ; Nag A; Thorner AR; Wollison B; Hansen DL; Ellervik C; El Fassi D; de Stricker K; Ocias LF; Brabrand M; Bjerrum OW; Overgaard UM; Frederiksen M; Kristensen TK; Kruse TA; Thomassen M; Mourits-Andersen T; Severinsen MT; Stentoft J; Starklint J; Neuberg DS; Kjaer L; Larsen TS; Hasselbalch HC; Lindsley RC; Mullally A
Blood Adv; 2022 Apr; 6(7):2107-2119. PubMed ID: 34507355
[TBL] [Abstract][Full Text] [Related]
15. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
18. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.
Anand S; Stedham F; Beer P; Gudgin E; Ortmann CA; Bench A; Erber W; Green AR; Huntly BJ
Blood; 2011 Jul; 118(1):177-81. PubMed ID: 21562050
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 mutation.
Merchant S
Int Rev Cell Mol Biol; 2021; 365():117-162. PubMed ID: 34756242
[TBL] [Abstract][Full Text] [Related]
20. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms.
Fernandes de Oliveira Costa A; Olops Marani L; Mantello Bianco T; Queiroz Arantes A; Aparecida Lopes I; Antonio Pereira-Martins D; Carvalho Palma L; Santos Scheucher P; Lilian Dos Santos Schiavinato J; Sarri Binelli L; Araújo Silva C; Kobayashi SS; Agostinho Machado-Neto J; Magalhães Rego E; Samuel Welner R; Lobo de Figueiredo-Pontes L
Front Immunol; 2022; 13():768592. PubMed ID: 36211444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
